pathophysiology chapter 7
TRANSCRIPT
![Page 1: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/1.jpg)
Chapter 7
Neoplasia
1
![Page 2: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/2.jpg)
NEOPLASIA• Means “new growth”• Implies abnormality of cellular
growth/tumor• Malignant neoplasm is cancer• Benign growth is generally easily cured• Malignant cancer may not be survivable• Cancer is associated with altered
expression of cellular genes
Neoplasia
2
![Page 3: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/3.jpg)
BENIGN VS. MALIGNANT GROWTH
Malignant Tumor• Can kill host if untreated• Confirmed by invasive or metastasizing
nature• Tissue-specific differentiation (does not
closely resemble tissue type of origin)• Greater degree of anaplasia indicates aggressive
malignancy• Grows rapidly, may initiate tumor vessel
growth, frequently necrotic, dysfunctional
3
![Page 4: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/4.jpg)
BENIGN VS. MALIGNANT GROWTH (CONT.)
4
![Page 5: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/5.jpg)
BENIGN VS. MALIGNANT GROWTH (CONT.)
Benign Tumor• Does not have potential to kill host, but
may be life-threatening because of its location
• Does not invade adjacent tissue or spread to distant sites
• Many are encapsulated• More closely resembles original tissue type• Grows more slowly, little vascularity, rarely
necrotic, often retains original function
5
![Page 6: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/6.jpg)
BENIGN VS. MALIGNANT GROWTH (CONT.)
Benign Tumor• “-oma” suffix indicates benign tumor
(adenoma)• “-carcinoma,” “-sarcoma” indicate
malignant tumors• Carcinoma: malignant tumor of epithelial
origin (adenocarcinoma)• Sarcoma: malignant tumor of mesenchymal
origin• Leukemia: malignant growth of white blood
cells
6
![Page 7: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/7.jpg)
EPIDEMIOLOGY AND CANCER RISK FACTORS
• Cancer is 2nd leading cause of death in the U.S.
• Most cancer deaths occur in individuals over age 55
• Men have 1:2 risk of developing cancer; women have 1:3 risk
• 5-year survival rate: 66%
7
![Page 8: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/8.jpg)
EPIDEMIOLOGY AND CANCER RISK FACTORS (CONT.)
8
![Page 9: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/9.jpg)
EPIDEMIOLOGY AND CANCER RISK FACTORS (CONT.)
• One third of cancer-related deaths may be attributable to lifestyle factors• Tobacco use• Nutrition• Obesity• Sun exposure (skin cancer)• Sexual exposure to HPV (cervical cancer)
• Early screening aids in early detection
9
![Page 10: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/10.jpg)
TOBACCO USE• Death rate from lung cancer has
dramatically increased (may be directly related to smoking)
• Lung cancer: leading cause of death in men and women; worst survival rate
• Also linked to pancreatic, kidney, bladder, mouth, esophageal, and cervical cancers
10
![Page 11: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/11.jpg)
TOBACCO USE (CONT.)
11
![Page 12: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/12.jpg)
TOBACCO USE (CONT.)• Two types of carcinogens
• Initiator (causes genetic damage)• Promoter (promotes tumor growth)
• Tobacco smoke contains both types• Second-hand smoke also increases risk for
lung cancer
12
![Page 13: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/13.jpg)
TOBACCO USE (CONT.)
13
![Page 14: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/14.jpg)
NUTRITION• Dietary factors believed to be related to
cancer risk• Fat• Fiber• Alcohol• Antioxidants
14
![Page 15: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/15.jpg)
GENETIC MECHANISMS OF CANCER
• Carcinogen• Potential cancer-causing agent
• Proto-oncogene• Overactivity of cancer-critical genes contributes to
cancer• Oncogene
• Proto-oncogene in its mutant overexpressed form• Tumor suppressor gene
• Too little gene activity; inhibits cell proliferation• Cancers may arise when tumor suppressor gene
function is lost or abnormally inhibited
15
![Page 16: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/16.jpg)
PROTO-ONCOGENES• Normal cellular genes that can be
transformed into oncogenes by activating (gain-of-function) mutations
• Code for• Growth factors• Receptors• Cytoplasmic signaling molecules• Nuclear transcription factors
16
![Page 17: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/17.jpg)
PROTO-ONCOGENES (CONT.)
17
![Page 18: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/18.jpg)
GROWTH FACTORS (MITOGENS)Small Cell−Manufactured Peptides • Secrete into extracellular space• Diffuse to nearby cells• Interact with receptors on target cell
surface• Activate signaling cascade; can produce
autocrine signaling
18
![Page 19: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/19.jpg)
GROWTH FACTOR RECEPTORS• Transmembrane proteins
• Mitogen-binding area on outside of cell• Enzyme-activating area on inside of cell
• Will bind with only one particular mitogen• Binding activates cell proliferation
19
![Page 20: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/20.jpg)
CYTOPLASMIC SIGNALING PATHWAYS
• Involve numerous enzymes and chemicals that normally function to transmit signals from activated receptors at cell surface to cell nucleus
• Mutant proto-oncogene can activate pathway, even when no signal received at cell surface
20
![Page 21: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/21.jpg)
TRANSCRIPTION FACTORS• Proteins that must be assembled at the
promoter area to begin gene transcription• Normally sequestered and prevented from
indiscriminate activity until appropriate signals cause their release
• Mutations may cause overproduction of transcription factors
21
![Page 22: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/22.jpg)
FROM PROTO-ONCOGENE TO ONCOGENE
• Proto-oncogenes become activated oncogenes when mutations alter their activity so that proliferation-promoting signals are generated inappropriately• Oncogenes introduced to host cell by
retrovirus• Proto-oncogene within cell suffers a
mutagenic event• DNA sequence may be lost/damaged and
allows proto-oncogene to become abnormally active
• Error in chromosome replication causes extra copies of proto-oncogene in the genome
22
![Page 23: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/23.jpg)
FROM PROTO-ONCOGENE TO ONCOGENE (CONT.)
23
![Page 24: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/24.jpg)
FROM PROTO-ONCOGENE TO ONCOGENE (CONT.)
• Retrovirus • HIV
• Kaposi’s sarcoma• Epstein-Barr virus
• Burkitt lymphoma• Human T-lymphocyte virus type 1
• Adult T-cell leukemia/lymphoma• Composed of RNA • Contains reverse transcriptase enzyme
• Directs synthesis of a DNA copy of viral RNA
24
![Page 25: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/25.jpg)
FROM PROTO-ONCOGENE TO ONCOGENE TRANSCRIPTION
FACTORS
25
![Page 26: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/26.jpg)
TUMOR-SUPPRESSOR GENES• Contribute to cancer only when not present• Both copies of tumor suppressor genes are
inactivated when cancer develops• One can inherit a defective copy of tumor
suppressor gene from 1 or both parents
26
![Page 27: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/27.jpg)
TUMOR-SUPPRESSOR GENES (CONT.)
27
![Page 28: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/28.jpg)
RB GENE• Codes for large protein in cell nucleus
(pRb) that is the “master break” for the cell cycle
• Blocks cell division• Binding transcription factors• Inhibits T factors from transcribing genes that
initiate cell cycle• Can be induced to release transcription
factors when sufficiently phosphorylated• An inactivating mutation of the Rb gene
removes 1 major restraint on cell division
28
![Page 29: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/29.jpg)
RB GENE (CONT.)
29
![Page 30: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/30.jpg)
P53 GENE• Most common tumor-suppressor gene
defect identified in cancer cells• More than ½ of all types of human tumors lack
functional p53• Inhibits cell cycling• Accumulates only after cellular (DNA)
damage• Binds to damaged DNA and stalls division
30
![Page 31: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/31.jpg)
P53 GENE (CONT.)
31
![Page 32: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/32.jpg)
P53 GENE (CONT.)• May direct cell to initiate apoptosis• Allows genetically damaged/unstable cells
to survive and continue to replicate• Chemotherapy/radiation
• Damages target cell to trigger p53-mediated cell death
• Cancer cells that lack functional p53 may be resistant to chemotherapy/radiation
32
![Page 33: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/33.jpg)
BRCA1 AND BRCA2 GENES• Breast cancer genes• Family history and inherited defect in
BRCA1 increases risk of breast and ovarian cancer
33
![Page 34: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/34.jpg)
BRCA1 AND BRCA2 GENES (CONT.)
34
![Page 35: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/35.jpg)
MULTISTEP NATURE OF CARCINOGENESIS
• Initiation• Promotion• Progression
35
![Page 36: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/36.jpg)
MULTISTEP NATURE OF CARCINOGENESIS (CONT.)
36
![Page 37: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/37.jpg)
MULTISTEP NATURE OF CARCINOGENESIS (CONT.)
37
![Page 38: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/38.jpg)
INITIATION• Initiating events
• Genetic mutations• Inappropriately activate proto-oncogenes• Inactivate tumor suppressor genes
• Proliferation• Required for cancer development (nonproliferating
cells cannot cause cancer)• Each type of cancer has its own
combination of mutations that lead to malignancy
38
![Page 39: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/39.jpg)
INITIATION (CONT.)
39
![Page 40: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/40.jpg)
INITIATION (CONT.)• Complete carcinogens
• Capable of initiating cell damage as well as promoting cellular proliferation
• Partial carcinogens• Promoters that stimulate growth• Incapable of causing genetic mutations sufficient
to singly initiate cancer
40
![Page 41: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/41.jpg)
PROMOTION• Stage during which mutant cell proliferates
• Activation of another oncogene• Inactivation of tumor suppressor gene• Nutritional factors• Infection
• Regulated by many hormonal growth factors (hormones may be promoters for certain cancers)• Estrogen• Testosterone
41
![Page 42: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/42.jpg)
PROGRESSION• Mutant, proliferating cells begin to exhibit
malignant behavior• Malignant cells commonly produce
telomerase (an enzyme that repairs telomeres and may be a key for attaining immortality)
• Cells whose phenotype gives them a growth advantage proliferate more readily
• Requires multiple steps
42
![Page 43: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/43.jpg)
PROGRESSION (CONT.)
43
![Page 44: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/44.jpg)
METASTASIS• Process by which cancer cells escape their
tissue of origin and initiate new colonies of cancer in distant sites• Specialized enzymes and receptors enable them
to escape their tissue of origin and metastasize
44
![Page 45: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/45.jpg)
METASTASIS (CONT.)
45
![Page 46: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/46.jpg)
PATTERNS OF SPREAD• Cancer cells generally spread via circulatory
or lymphatic systems• Tumor markers help identify parent tissue of
cancer origin• Rely on some retention of parent tumor
characteristics• Some released into circulation• Others identified through biopsy• Enzymes typically used as tumor markers• Help track tumor activity
46
![Page 47: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/47.jpg)
ANGIOGENESIS• Process by which cancer tumor forms new
blood vessels in order to grow• Usually does not develop until late stages of
development• Triggers are not generally understood• Inhibition of angiogenesis is important
therapeutic goal
47
![Page 48: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/48.jpg)
GRADING AND STAGING OF TUMORS
• To predict clinical behavior of malignant tumor and guide therapeutic management
• Grading• Histologic characterization of tumor cells • Degree of anaplasia• 3 or 4 classes of increasing degrees of malignancy
48
![Page 49: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/49.jpg)
GRADING AND STAGING OF TUMORS (CONT.)
• Staging• Location and patterns of spread within the host• Tumor size, extent of local growth, lymph node
and organ involvement, distant metastasis• TNM system most widely used• Results of staging determine treatment
modality
49
![Page 50: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/50.jpg)
GRADING AND STAGING OF TUMORS
![Page 51: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/51.jpg)
EFFECTS OF CANCER ON THE BODY
• Depends on location of tumor and extent of metastasis
• Early stages may be symptomatic• Tumor increases in size and spreads; more
symptoms become apparent
![Page 52: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/52.jpg)
EFFECTS OF CANCER ON THE BODY (CONT.)
![Page 53: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/53.jpg)
WARNING SIGNS OF CANCER• Change in bowel or bladder habits• A sore that does not heal• Unusual bleeding or discharge• Thickening or lump in breast or elsewhere• Indigestion or difficulty swallowing• Obvious change in wart or mole• Nagging cough or hoarseness
![Page 54: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/54.jpg)
WARNING SIGNS OF CANCER IN CHILDREN
• Continued, unexplained weight loss• Headaches with vomiting in the morning• Increased swelling or persistent pain in
bones or joints• Lump or mass in abdomen, neck, or
elsewhere• Development of whitish appearance in pupil
of the eye• Recurrent fevers not caused by infections• Excessive bleeding or bruising• Noticeable paleness or prolonged tiredness
![Page 55: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/55.jpg)
PAIN• Common and feared complication• May be due to metastasis, tissue
destruction/inflammation• May be caused by cancer treatment• Usually controlled with analgesics
![Page 56: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/56.jpg)
CACHEXIA AND IMMUNE SYSTEM DEFICITS
• Cachexia• Overall weight loss and generalized weakness
• Loss of appetite (anorexia)• Increased metabolic rate• Nausea/vomiting
• Immune system suppressed by cancer cell secretions
• Some cancers can elude immune system detection
![Page 57: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/57.jpg)
BONE MARROW SUPPRESSION• Contributes to anemia, leukopenia, and
thrombocytopenia• Due to invasion and destruction of bone
marrow cells, poor nutrition, and chemotherapy
• Anemia: Deficiency in circulating red blood cells
![Page 58: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/58.jpg)
LEUKOPENIA• Deficiency in circulating white blood cells
• Primary cause• Malignant invasion of bone marrow
• Contributing factors• Malnutrition• Chemotherapy
• Opportunistic organisms can only infect immunocompromised host
• Infections difficult to manage, prevent
![Page 59: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/59.jpg)
THROMBOCYTOPENIA• Deficiency in circulating platelets
• Important mediators in blood clotting• Predispose to life-threatening hemorrhage
• Anemia, leukopenia, thrombocytopenia can all be managed by blood replacement therapy
![Page 60: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/60.jpg)
OTHER EFFECTS• Hair loss and mucositis
• Complications of chemotherapy and radiation therapy• Mucositis primary source of cancer pain and anorexia• May provide a portal for infection
• Paraneoplastic syndromes • Hypercalcemia• Cushing syndrome secondary to ACTH secretion• Hyponatremia and water overload secondary to
excess ADH secretion
![Page 61: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/61.jpg)
CANCER THERAPY• Early detection best prognosis for cure• Mainstays of therapy
• Surgery• Radiation therapy• Chemotherapy• Drug therapy
• Emerging therapies• Immunotherapy• Targeted molecular therapies• Stem cell transplantation
![Page 62: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/62.jpg)
CANCER THERAPY (CONT.)
![Page 63: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/63.jpg)
SURGERY• Majority of patients with solid tumors are
treated surgically• Main benefit: removal of tumor with
minimal damage to other body cells• Lymph nodes biopsied and/or removed• Commonly accompanied by radiation
therapy or chemotherapy
![Page 64: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/64.jpg)
RADIATION THERAPY
• Kills tumor cells by damaging nuclear DNA• Kills cells that are nonresectable due to
location, missed by surgery, or undetected• May not kill cells directly, but initiates
apoptosis• Small doses of radiation over several
treatments (difficult to kill at once because cells on different cycles)
• Some normal cells killed during radiation therapy
![Page 65: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/65.jpg)
DRUG THERAPY• Systemic administration of anticancer
chemicals to treat cancers known or suspected to be disseminated in the body
• Finds cancer cell targets in the body• Most are cytotoxic• Not selective for tumor cells (normal cell
death may also occur)
![Page 66: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/66.jpg)
DRUG THERAPY (CONT.)• Most effective on rapidly dividing cells• Several courses ensure all cancer cells
killed• Serious side effect: bone marrow
suppression
![Page 67: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/67.jpg)
IMMUNOTHERAPY• Primarily involves use of:
• Interferons• Glycoproteins produced by immune cells in response
to viral infection• Interleukins
• Peptides produced and secreted by white blood cells• Monoclonal antibodies
• Antibodies with identical structure that bind with specific target antigens
• Generally used as adjuncts to surgery, irradiation, and chemotherapy
![Page 68: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/68.jpg)
GENE AND MOLECULAR THERAPY
• May have high therapeutic potential• May be used to suppress overactive
oncogenes or replenish missing tumor suppressor function
• Current uses• Genetic alteration of tumor cells to make them
more susceptible to cytotoxic agents or immune recognition
• Genetic alteration of immune cells to make them more efficient killers of tumor cells
• Can be directed at cells other than cancer cells
![Page 69: PathoPhysiology Chapter 7](https://reader035.vdocument.in/reader035/viewer/2022062412/58e7d6cf1a28ab3a578b4ff7/html5/thumbnails/69.jpg)
STEM CELL TRANSPLANTATION• Used to manage life-threatening disorders
in which patient’s bone marrow cannot manufacture white blood cells, red blood cells, or platelets
• Also applied to other malignancies and to nonmalignant disorders
• Provides a method to restore bone marrow function after high-dose irradiation or chemotherapy